Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Paul Schimmel sold 27,823 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $150.00, for a total transaction of $4,173,450.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $1,500,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
NASDAQ:ALNY traded down $1.36 during midday trading on Friday, reaching $95.08. The stock had a trading volume of 1,956,027 shares, compared to its average volume of 1,427,683. Alnylam Pharmaceuticals, Inc. has a 12-month low of $47.16 and a 12-month high of $153.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23. The firm has a market cap of $9,660.53, a price-to-earnings ratio of -17.54 and a beta of 2.68.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm had revenue of $37.90 million during the quarter, compared to analysts’ expectations of $19.31 million. During the same quarter last year, the business earned ($1.32) earnings per share. The business’s quarterly revenue was up 116.6% on a year-over-year basis. analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.02 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its position in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 167 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Alnylam Pharmaceuticals by 0.4% in the third quarter. Dimensional Fund Advisors LP now owns 180,058 shares of the biopharmaceutical company’s stock valued at $21,156,000 after acquiring an additional 629 shares during the period. Great West Life Assurance Co. Can lifted its holdings in Alnylam Pharmaceuticals by 8.5% in the third quarter. Great West Life Assurance Co. Can now owns 8,904 shares of the biopharmaceutical company’s stock valued at $1,050,000 after acquiring an additional 695 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 10.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 7,200 shares of the biopharmaceutical company’s stock valued at $915,000 after acquiring an additional 700 shares during the period. Finally, Public Employees Retirement Association of Colorado lifted its holdings in Alnylam Pharmaceuticals by 4.4% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 17,321 shares of the biopharmaceutical company’s stock valued at $2,201,000 after acquiring an additional 736 shares during the period. Hedge funds and other institutional investors own 92.28% of the company’s stock.
Several brokerages have commented on ALNY. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, March 14th. Credit Suisse Group increased their price target on shares of Alnylam Pharmaceuticals from $151.00 to $154.00 and gave the company an “outperform” rating in a research note on Tuesday, March 13th. JMP Securities increased their price target on shares of Alnylam Pharmaceuticals from $169.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, March 26th. Leerink Swann raised their target price on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research report on Thursday, January 25th. Finally, Evercore ISI started coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 28th. They set a “line” rating and a $143.00 target price on the stock. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $134.15.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/paul-schimmel-sells-27823-shares-of-alnylam-pharmaceuticals-inc-alny-stock.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.